COMMUNICATION:
Cyclooxygenase-1 Behaves as a Delayed Response Gene in PC12 Cells Differentiated by Nerve Growth Factor*

(Received for publication, May 16, 1997, and in revised form, June 3, 1997)

Mitchell D. Kaplan Dagger , John A. Olschowka Dagger and M. Kerry O'Banion Dagger §

From the Departments of Dagger  Neurobiology & Anatomy and § Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Treatment of PC12 cells with nerve growth factor (NGF) results in a differentiation program characterized by expression of immediate early and delayed response genes. In this program, morphological changes such as neurite extension are accompanied by phenotypic changes in enzyme expression, including an increased capacity for prostaglandin synthesis. Cyclooxygenase (COX), the enzyme responsible for prostanoid production, exists as two isoforms: constitutive COX-1 and inducible COX-2. We report that COX-1 behaves as a delayed response gene in PC12 cells exposed to NGF. Six hours following NGF treatment, COX-1 mRNA levels were elevated in PC12 cells, reaching nearly 5-fold above basal levels at 12 h. This increase was blocked by cycloheximide and was accompanied by concomitant increases in COX-1 protein and enzyme activity. COX-1 protein remained elevated for at least 10 days and localized to the cytoplasm and neurites of NGF-differentiated PC12 cells. Moreover, basic fibroblast growth factor, but not epidermal growth factor, caused similar increases in COX-1, which is consistent with expression characteristics of other delayed response genes in PC12 cells. This is the first example of neurotrophic factor regulation of cyclooxygenase and may have important implications for determination of the differentiated phenotype in PC12 cells.


INTRODUCTION

Nerve growth factor (NGF)1 is a member of the neurotrophin family of growth factors and has long been known to maintain sympathetic neurons and certain populations of sensory neurons in the periphery (1-3). Phenotypic changes in response to NGF have been studied in PC12, a cell line derived from rat pheochromocytoma (4). A neuronal phenotype is induced by NGF exposure, which promotes differentiation and survival of these cells (5). NGF also induces several delayed response gene products including VGF (6, 7), GAP43 (8), and transin (9). Like NGF, basic fibroblast growth factor (bFGF) induces PC12 cell differentiation (10), whereas epidermal growth factor (EGF) is mitogenic in PC12 cells (11). These differential effects have been used to characterize the signal transduction pathway leading to the differentiated phenotype. NGF and bFGF both cause a prolonged activation of Ras resulting in a prolonged increase of extracellular signal-regulated kinase activity. In contrast, EGF causes transient activation of Ras and extracellular signal-regulated kinase (12). One proposed mechanism of delayed response gene induction is through the prolonged activation of Ras leading to the phosphorylation of the cAMP regulatory element-binding protein for up to several hours (13, 14) that, along with immediate early gene products, leads to subsequent delayed response gene expression.

Cyclooxygenase (COX), the enzyme responsible for the conversion of arachidonic acid to prostaglandin H2, exists as two isoforms, COX-1 and COX-2. In non-neuronal cells COX-2 behaves similarly to other immediate early genes in that it is rapidly and transiently induced by various growth factors and cytokines without requiring new protein synthesis (15, 16). It is also rapidly induced in central nervous system neurons through synaptic activation (17). COX-1, on the other hand, is constitutively expressed in a variety of cell types (16), although a few examples of COX-1 regulation in non-neuronal cells have been reported (18-20). Regulation of COX by neurotrophic factors has not been previously demonstrated in neuronal cells; however, NGF-induced differentiation of PC12 cells leads to elevated prostaglandin levels (21). We report for the first time that NGF induces COX-1 in PC12 cells, that this induction is inhibited by cycloheximide, and that bFGF (but not EGF) also induces COX-1, suggesting that COX-1 behaves as a delayed response gene in these cells.


EXPERIMENTAL PROCEDURES

Materials

Dulbecco's modified Eagle's medium, human recombinant bFGF, human recombinant EGF, fetal bovine serum, horse serum, penicillin-streptomycin, and TRIzol reagent were obtained from Life Technologies, Inc. A monoclonal antibody to COX-2 was purchased from Transduction Labs (Lexington, KY) and was found to have cross-reactivity to both ovine (Caymen Chemical, Ann Arbor, MI) and rat COX-1 antigen (a gift from Phyllis Whiteley, Roche Bioscience, Palo Alto, CA). Initial experiments were performed using NGF provided by Dr. Eugene Johnson who also kindly supplied the neutralizing antibody to NGF. Later experiments were performed using 2.5s NGF purchased from Life Technologies, Inc. No differences in response were noted between the two sources of NGF. Texas red-conjugated goat anti-mouse polyclonal antibodies were purchased from Jackson ImmunoResearch (West Grove, PA). [alpha -32P]dCTP and PGE2 RIA kits were purchased from NEN Life Science Products. Arachidonic acid was purchased from New Check Prep (Elysian, MN). All other products were from Sigma.

Cell Culture

PC12 cells were grown on plastic tissue culture dishes in Dulbecco's modified Eagle's medium with 5% heat-inactivated horse serum and 5% fetal bovine serum in the presence of penicillin-streptomycin. For most studies, cells were plated at a density of 103 cells/cm2 and were grown to 70-80% confluency prior to the start of each experiment.

Immunocytochemistry and Subcloning of PC12 Cells

PC12 cells were plated at a density of 1000 cells/well into 24-well dishes containing 12-mm glass coverslips coated with poly-D-lysine. Cells were treated with 50 ng/ml NGF or vehicle for 3 days, fixed with 4% paraformaldehyde for 10 min, and washed with PBS. Coverslips were incubated in PBS-T for 10 min followed by a 20-min incubation in -20 °C methanol. Samples were rehydrated in PBS-T for 10 min, blocked for 1 h in 10% normal goat serum, and then incubated in primary antibody (1:1000) for 2 days at 4°C. Following extensive washing with PBS-T, samples were incubated in Texas red-conjugated secondary antibody (1:2000) for 2 h. Coverslips were thoroughly washed, partially dried, and placed on glass slides coated with 50 µl of Prolong purchased from Molecular Probes (Eugene, OR). Cells were viewed by epifluorescent microscopy, and images were captured by a Cohu (San Diego, CA) 4910 CCD video camera attached to a Zeiss Axioplan microscope and visualized using NIH Image/Adobe Photoshop software. COX was detected in parental PC12 cells; however, signal intensity varied within the population. We subcloned PC12 cells by standard methods to develop cell lines that uniformly expressed COX. Briefly, cells were plated in 96-well dishes at a density of approximately 1 cell/well. Following 2-3 passages, subclones were plated separately onto poly-D-lysine-coated glass coverslips and visualized following NGF treatment as described above. The majority of subclones tested expressed COX uniformly as detected by immunofluorescence, and two subclones (PCX and PCX25) with bright COX signal were chosen for further study.

Western Blot Analysis

To measure COX protein levels, parental PC12, PCX, or PCX25 cells were plated in 6-well dishes. After treatment, cells were washed three times with ice-cold PBS and collected in 200 µl of Laemmli sample buffer. Samples were sonicated, and protein concentrations were determined using the bicinchoninic acid method (Micro-BCA kit) purchased from Pierce. Ten-microgram protein samples were separated by SDS-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA). Blots were blocked in Tris-buffered saline containing 0.1% Tween 20, 2% BSA, and 3% nonfat dry milk for 1 h and then incubated with primary antibody (1:1000) overnight in the same buffer. Following extensive washing and incubation for 2 h with peroxidase-linked secondary antibody at 1:5000 (Amersham Corp.), signals were visualized by enhanced chemiluminescence (ECL; Amersham Corp.) and exposure to Kodak X-AR film. Laser densitometry and quantification were accomplished with a system from Molecular Dynamics (Sunnyvale, CA).

Cyclooxygenase Activity Determination

Cyclooxygenase activity was measured by incubating cells for 15 min with 30 µM arachidonic acid as described previously (22). PGE2 levels were determined by RIA and normalized to total cellular protein determined by the bicinchoninic acid method. In all accumulation and activity experiments, samples were collected from five or six parallel cultures.

RNA Preparation, Northern Blot Analysis, and Reverse Transcription-Polymerase Chain Reaction

Total RNA was isolated from 60-mm plates using guanidinium isothiocyanate lysis followed by centrifugation through a cesium chloride cushion (23) or with TRIzol reagent. RNAs were quantified by absorbance measurements at 260 nm and subjected to Northern blot analysis as described previously (24) using random prime 32P-labeled probes. These consisted of EcoRI fragments of murine COX-1 and COX-2 cDNA and a purchased fragment of human G3PDH from CLONTECH (Palo Alto, CA). RNA molecular weight markers (Life Technologies, Inc.) were electrophoresed in parallel and were visualized by ethidium bromide staining. Hybridization signals were detected and quantified using a Molecular Dynamics PhosphorImager.

For COX sequence determination, total RNA from NGF-treated PCX cells was reverse transcribed using the Superscript II kit (Life Technologies, Inc.). Complementary DNA samples were subjected to 40 cycles of polymerase chain reaction using the following primers: for COX-1, 5'-TTCTGCCCTCTGTACCCAAA-3' (upper primer) and 5'-AAGGATGAGGCGAGTGGTCT-3' (lower primer); for COX-2, 5'-GGTGTGAAAGGAAATAAGGAAC-3' (upper primer) and 5'-GGAGGATGGAGTTGTTGTAGAG-3' (lower primer). Reaction products were gel-purified and sequenced by the fluorescent dideoxy sequencing method using a 373 DNA sequencer from Applied Biosystems (Foster City, CA) at the University of Rochester Nucleic Acid Core facility.


RESULTS

NGF induced COX protein in a dose-dependent fashion in PC12 cells (Fig. 1A). This induction was 9.3 ± 1.4-fold over basal levels (mean ± S.E.; n = 4) at 50 ng/ml of NGF, a dose typically used to differentiate PC12 cells (25), and was significantly blocked (p < 0.02) when added NGF (50 ng/ml) was preincubated for 30 min with 10-fold excess neutralizing antibody to NGF (Fig. 1B). These experiments were carried out after 4 days of NGF treatment; however, COX protein levels remained elevated for at least 10 days (data not shown).


Fig. 1. NGF induces COX in PC12 cells. In A, PC12 cells were treated for 4 days with the indicated concentrations of NGF. Cell lysates were subjected to Western blot analysis with antibody recognizing both COX-1 and COX-2 in rat. In the lane on the far right, lysate was from cells treated with 50 ng/ml NGF that had been preincubated with 10-fold excess neutralizing anti-NGF antibody (37 °C for 30 min). In B, data represent the mean laser densitometric values ± S.E. (n = 4) of COX protein levels relative to controls following treatment as described in A. **, p < 0.02 versus 50 ng/ml of NGF, two-tailed Student's t test).
[View Larger Version of this Image (30K GIF file)]

Initial immunocytochemical analysis revealed expression of COX in parental PC12 cells; however, signal intensity of COX immunofluorescence varied within the population. To obtain a more homogenous cell population for COX expression, we subcloned PC12 cells and selected two subclones, PCX and PCX25, to carry out the remainder of our experiments. As illustrated in Fig. 2, COX was readily detected in the cytoplasm and neurites of PCX cells after NGF-induced differentiation. A similar pattern was seen in the parental cell line and in PCX25 cells (data not shown).


Fig. 2. Localization of COX protein in PCX cells. PCX cells were cultured on poly-D-lysine-coated glass coverslips ± 50 ng/ml NGF for 3 days. Cells were fixed in 4% paraformaldehyde and subjected to immunofluorescence for COX as described under "Experimental Procedures." Scale bar, 25 µm.
[View Larger Version of this Image (42K GIF file)]

To determine which isoform of COX was expressed in PCX cells, total RNA was reverse-transcribed and amplified by polymerase chain reaction. No COX-2 product was detected after 40 cycles of polymerase chain reaction, which is consistent with previously published data (26), whereas a fragment of the expected size for COX-1 was generated with COX-1-specific primers. This fragment was gel-purified and sequenced to verify that COX-1 was present in these cells (data not shown).

We evaluated whether COX-1 was functional in PCX cells by assessing prostaglandin production in NGF-differentiated cells. Four days following the addition of NGF, neuronal PCX cells showed a 11.5-fold increase (n = 5) in endogenous PGE2 accumulation over 4 h relative to naive cells (Fig. 3A). To confirm that this increase in PGE2 was due to increased COX-1 activity, we tested whether exogenous substrate for COX (arachidonic acid) would lead to increases in PGE2 production. Fig. 3B illustrates that COX-1 activity peaks at 2 days with a 9.7-fold induction over basal levels seen prior to NGF treatment (n = 5). Fig. 3C shows COX activity in differentiated PCX cells treated with NGF for 4 days to be 9.9-fold over levels in untreated cells at day 4 (n = 5), and this increase was inhibited by the non-steroidal anti-inflammatory agent indomethacin, with an IC50 of 35 nM, similar to that previously reported for COX-1 (27).


Fig. 3. NGF induces endogenous PGE2 production and COX activity in PCX cells. In A, PCX cells were cultured in 12-well plates for 4 days ± 50 ng/ml NGF, rinsed, and placed in fresh minimal essential medium containing 0.3% BSA; samples were collected 4 h later. In B, PCX cells were cultured ± 50 ng/ml NGF for 0, 1, 2, and 4 days, rinsed, and placed in fresh minimal essential medium, 0.3% BSA containing excess arachidonic acid (30 µM) for 15 min; samples were collected. In C, PCX cells were cultured in 12-well plates for 4 days ± 50 ng/ml NGF. Cells were pretreated with the indicated concentrations of indomethacin 30 min prior to COX activity determination as described for B. Indomethacin was present throughout the activity assay. In all experiments PGE2 production was quantified by RIA and normalized to total cellular protein. Values represent the mean ± S.E. of five independent cultures.
[View Larger Version of this Image (15K GIF file)]

Northern blot analysis revealed that COX-1 mRNA was elevated 6 h following NGF treatment (Fig. 4A) with peak levels reached at 12 h (4.7 ± 0.8-fold over basal levels, n = 3; Fig. 4B). COX-1 message remained elevated at 24 and 48 h. No message for COX-2 was detected (data not shown). Only a minimal increase in COX-1 message over basal levels was seen at 3 h suggesting that COX-1 requires new protein synthesis to be expressed. Indeed, pretreatment with cycloheximide (25 µM, applied 30 min prior to NGF) prevented COX-1 expression at 8 h (Fig. 4C), indicating that COX-1 has characteristics of a delayed response gene following NGF treatment.


Fig. 4. Increases in COX-1 message following NGF treatment depend on new protein synthesis. In A, total RNA (10 µg) isolated from PCX cells treated for various intervals with 50 ng/ml NGF was separated by formaldehyde-agarose gel electrophoresis and subjected to Northern blot hybridization with random prime labeled COX-1 and G3PDH probes. In B, images of replicate experiments were captured by a Molecular Dynamics PhosphorImager. Values were normalized to G3PDH and then graphically represented as the relative induction over control values (mean ± S.E.; n = 3). In C, PCX cells were pretreated for 30 min with 25 µM cycloheximide. Cultures were then treated ± 100 ng/ml NGF for 8 h prior to collection for Northern blot analysis as described for A. C, control; N, NGF-treated; CHX, cycloheximide-treated RNA samples. Data are representative of three replicate experiments.
[View Larger Version of this Image (35K GIF file)]

To further characterize the induction of COX-1 in PC12 cells, we tested whether bFGF or EGF had any influence on COX-1 expression. bFGF causes neuronal differentiation of PC12 cells, whereas EGF acts solely as a mitogen (10, 11). Fig. 5A shows that bFGF caused a similar increase in COX-1 message levels by 6 h as compared with NGF (Fig. 4A); however, EGF had little to no effect on mRNA levels for COX-1. This pattern of induction was replicated at the protein level (Fig. 5B). The time course for the induction of COX-1 by bFGF was similar to that seen following exposure to NGF, and similar results were seen with PCX25 cells (data not shown).


Fig. 5. Basic FGF, but not EGF, induces COX-1 in PCX cells. In A, PCX cells treated with either 50 ng/ml bFGF or 50 ng/ml EGF were collected and subjected to Northern blot analysis as described for Fig. 4A. Data are representative of two separate experiments. In B, lysates from PCX cells treated as in A were collected at various time intervals and analyzed by Western blot as described for Fig. 1A. Identical results were obtained with a second PC12 subclone, PCX25.
[View Larger Version of this Image (63K GIF file)]


DISCUSSION

In many cell systems COX-1 is constitutively expressed (16, 22, 28), but there are some instances where COX-1 is regulated. For example, COX-1 message is induced in mouse osteoblastic MC3T3 cells treated with bFGF (18) and during phorbol ester-induced differentiation of THP-1 cells, a human monocytic leukemia cell line (20). In contrast to the transient induction of immediate early genes like c-fos (29) and certain tetradecanoyl phorbol acetate-induced sequences (26) in PC12 cells, the induction of COX-1 message was delayed and persisted following NGF and bFGF treatment in PCX cells (Figs. 4A and 5A). This pattern of expression is similar to other delayed response gene products in PC12 cells such as transin and VGF. Like COX-1, transin mRNA levels increase in response to NGF and bFGF, but not EGF, and this increase in message is blocked by cycloheximide (9). VGF shows similar inductive properties (7). COX-1 induction by NGF and bFGF, but not EGF, is consistent with the idea that COX-1 induction is through the prolonged activation of Ras. Persistent Ras activation by either NGF or bFGF leads to neurite extension, whereas the transient activation of this signaling pathway by EGF does not (12).

The induction of COX-1 by NGF in PC12 cells suggests that it may play a physiologic role in the differentiated phenotype. PC12 cells have been used to investigate the tyrosine hydroxylase pathway involved in the production of the bioactive amines: dopamine, norepinephrine, and serotonin (4). Interestingly, it has been shown that pharmacologic manipulation of PC12 cells with PGE2 leads to an induction of aromatic L-amino acid decarboxylase (30), an enzyme directly involved in the synthesis of these neurotransmitters. COX-1 may be intimately involved in determination of the differentiated phenotype of PC12 cells since prostaglandin levels have been reported to be elevated as early as 15 min following NGF treatment; however, this increase does not affect the morphological phenotype since indomethacin does not hinder NGF-induced neurite extension in PC12 cells (21) or in our PCX subclone (data not shown).

Studies are under way to further understand the mechanism of COX-1 induction in these cells and to address whether other characteristics of the differentiated phenotype depend on COX-1 activity.


FOOTNOTES

*   This work was supported by National Institutes of Health Grants LEAD AG09016 and R29 NS33553 and Dentist Scientist Award K16 DE00159 and by the Lucille P. Markey Charitable Trust.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom correspondence should be addressed: University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave., Box 603, Rochester, NY 14642. Tel.: 716-275-5185; Fax: 716-273-1132; E-mail: obanion{at}medinfo.rochester.edu.
1   The abbreviations used are: NGF, nerve growth factor; bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; COX, cyclooxygenase; PBS, phosphate-buffered saline; PBS-T, phosphate-buffered saline with 0.4% Triton X-100; RIA, radioimmunoassay; PGE2, prostaglandin E2; G3PDH, glyceraldehyde-3-phosphate dehydrogenase; BSA, bovine serum albumin.

ACKNOWLEDGEMENTS

We thank Eugene Johnson for gifts of NGF and neutralizing antibody to NGF, Phyllis Whiteley for recombinant rat COX-1 protein, and Robert Freeman and Larry Tabak for helpful suggestions.


REFERENCES

  1. Levi-Montalcini, R., and Angeletti, P. U. (1963) Dev. Biol. 7, 653-657
  2. Barde, Y.-A. (1989) Neuron 2, 1525-1534 [Medline] [Order article via Infotrieve]
  3. Crowley, C., Spencer, S. D., Nishimura, M. C., Chen, K. S., Pitts-Meek, S., McMahon, S. B., Shelton, D. L., Levinson, A. D., and Phillips, H. S. (1994) Cell 76, 1001-1011 [Medline] [Order article via Infotrieve]
  4. Greene, L. A., and Tischler, A. S. (1976) Proc. Natl. Acad. Sci. U. S. A. 73, 2424-2428 [Abstract]
  5. Rukenstein, A., Rydel, R. E., and Greene, L. A. (1991) J. Neurosci. 11, 2552-2563 [Abstract]
  6. Levi, A., Eldridge, J. D., and Paterson, B. M. (1985) Science 229, 393-395 [Medline] [Order article via Infotrieve]
  7. Salton, S. R., Fischberg, D. J., and Dong, K. W. (1991) Mol. Cell. Biol. 11, 2335-2349 [Medline] [Order article via Infotrieve]
  8. Federoff, H., Grabczyk, E., and Fishman, M. (1988) J. Biol. Chem. 263, 19290-19295 [Abstract/Free Full Text]
  9. Machida, C. M., Rodland, K. D., Matrisian, L., Magun, B. E., and Ciment, G. (1989) Neuron 2, 1587-1596 [Medline] [Order article via Infotrieve]
  10. Rydel, R. E., and Greene, L. A. (1987) J. Neurosci. 7, 3639-3653 [Abstract]
  11. Huff, K., End, D., and Guroff, G. (1981) J. Cell Biol. 88, 189-198 [Abstract/Free Full Text]
  12. Qui, M.-S., and Green, S. H. (1992) Neuron 9, 705-717 [Medline] [Order article via Infotrieve]
  13. Bonni, A., Ginty, D. D., Dudek, H., and Greenberg, M. E. (1995) Mol. Cell. Neurosci. 6, 168-183 [CrossRef][Medline] [Order article via Infotrieve]
  14. Segal, R. A., and Greenberg, M. E. (1996) Annu. Rev. Neurosci. 19, 463-489 [CrossRef][Medline] [Order article via Infotrieve]
  15. O'Banion, M. K., Winn, V., and Young, D. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4888-4892 [Abstract]
  16. Herschman, H. R., Gilbert, R. S., Xie, W., Luner, S., and Reddy, S. T. (1995) Adv. Prostaglandin Thromboxane Leukotriene Res. 23, 23-28 [Medline] [Order article via Infotrieve]
  17. Yamagata, K., Andreasson, K. I., Kaufmann, W. E., Barnes, C. A., and Worley, P. F. (1993) Neuron 11, 371-386 [Medline] [Order article via Infotrieve]
  18. Kawaguchi, H., Pilbeam, C. C., Gronowicz, G., Abreu, C., Fletcher, B. S., Herschman, H. R., Raisz, L. G., and Hurley, M. M. (1995) J. Clin. Invest. 96, 923-930 [Medline] [Order article via Infotrieve]
  19. Hamasaki, Y., Kitzler, J., Hardman, R., Nettesheim, P., and Eling, T. E. (1993) Arch. Biochem. Biophys. 304, 226-234 [CrossRef][Medline] [Order article via Infotrieve]
  20. Smith, C. J., Morrow, J. D., Roberts, L. J., II, and Marnett, L. J. (1993) Biochem. Biophys. Res. Commun. 192, 787-793 [CrossRef][Medline] [Order article via Infotrieve]
  21. DeGeorge, J. J., Walenga, R., and Carboetto, S. (1988) J. Neurosci. Res. 21, 323-332 [Medline] [Order article via Infotrieve]
  22. O'Banion, M. K., Dusel, J. C., Chang, J. W., Kaplan, M. D., and Coleman, P. D. (1996) J. Neurochem. 66, 2532-2540 [Medline] [Order article via Infotrieve]
  23. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. (1979) Biochemistry 18, 5294-5299 [Medline] [Order article via Infotrieve]
  24. O'Banion, M. K., Sadowski, H. B., Winn, V., and Young, D. A. (1991) J. Biol. Chem. 266, 23261-23267 [Abstract/Free Full Text]
  25. Greene, L. A., Aletta, J. M., Rukenstein, A., and Green, S. H. (1987) Methods Enzymol. 147, 207-216 [Medline] [Order article via Infotrieve]
  26. Kujubu, D. A., Lim, R. W., Varnum, B. C., and Herschman, H. R. (1987) Oncogene 1, 257-262 [Medline] [Order article via Infotrieve]
  27. Vane, J. R., and Botting, R. M. (1995) Adv. Prostaglandin Thromboxane Leukotriene Res. 23, 41-48 [Medline] [Order article via Infotrieve]
  28. Pritchard, K. A., Jr., O'Banion, M. K., Miano, J. M., Vlasic, N., Bhatia, U. G., Young, D. A., and Stemerman, M. B. (1994) J. Biol. Chem. 269, 8504-8509 [Abstract/Free Full Text]
  29. Greenberg, M. E., Greene, L. A., and Ziff, E. B. (1985) J. Biol. Chem. 260, 14101-14110 [Abstract/Free Full Text]
  30. Li, X.-M., Juorio, A. V., and Boulton, A. A. (1994) Neurochem. Res. 19, 591-595 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.